AVAX Technologies (OTCMKTS:AVXT) and Anixa Biosciences (NASDAQ:ANIX) Critical Analysis
by Kim Johansen · The Markets DailyAVAX Technologies (OTCMKTS:AVXT – Get Free Report) and Anixa Biosciences (NASDAQ:ANIX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.
Institutional and Insider Ownership
29.1% of Anixa Biosciences shares are held by institutional investors. 6.0% of AVAX Technologies shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares AVAX Technologies and Anixa Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AVAX Technologies | N/A | N/A | N/A |
| Anixa Biosciences | N/A | -70.95% | -62.53% |
Valuation and Earnings
This table compares AVAX Technologies and Anixa Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AVAX Technologies | N/A | N/A | N/A | N/A | N/A |
| Anixa Biosciences | $210,000.00 | 431.10 | -$10.93 million | ($0.33) | -8.18 |
AVAX Technologies has higher earnings, but lower revenue than Anixa Biosciences.
Analyst Recommendations
This is a breakdown of current ratings and price targets for AVAX Technologies and Anixa Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AVAX Technologies | 0 | 0 | 0 | 0 | 0.00 |
| Anixa Biosciences | 1 | 1 | 2 | 0 | 2.25 |
Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 214.81%. Given Anixa Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than AVAX Technologies.
Summary
Anixa Biosciences beats AVAX Technologies on 6 of the 8 factors compared between the two stocks.
About AVAX Technologies
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.